Answers are grounded in this paper and cite their sources.
Prostatic adenocarcinoma (PAC) is the second most prevalent cancer and the fifth leading cause of cancer death in men worldwide. Additionally, pathologists may face problems diagnosing it reliably and may need more than one marker. Thus, the search for new immunohistochemical biomarkers becomes mandatory. This study aims to investigate P4HB and SOX4 expression in prostatic carcinoma, their possible roles, and clinical significance.
No takes yet. Share an insight, caveat, or question.
Dawoud et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: